Treatment Guideline Chart

Menopause is associated with decreased estrogen production which leads to vasomotor symptoms and vulvovaginal atrophy. The woman may experience hot flushes, night sweats, dyspareunia or vaginal dryness. Spontaneous or natural menopause occurs when the final menstrual period is confirmed after 12 consecutive months of amenorrhea with no pathological cause. Induced menopause is the permanent cessation of menstruation after bilateral oophorectomy (ie surgical menopause) or iatrogenic ablation of ovarian function (eg pelvic radiation therapy, chemotherapy).


Menopause & Hormone Therapy References

  1. Bélisle S, Blake J, Basson R, et al. Canadian consensus conference on menopause, 2006 update. J Obstet Gynaecol Can. 2006 Feb;28(2)(Suppl 1):S7-S94. PMID: 16626522
  2. American Society for Reproductive Medicine. Estrogen and progesterone therapy in postmenstrual women [summary from National Guideline Clearinghouse]. Fertil Steril. 2004;81(1):231-241. [DateAccess]
  3. Cummings DM. Postmenopausal hormone replacement therapy. Clin Fam Pract. 2002 Mar;4(1):135-154
  4. Cobin RH, Futterweit W, Ginzburg SB, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract. 2006 May;12(3):315-337. PMID: 16772207
  5. Goodman NF, Cobin RH, Ginzburg SB, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of menopause. Endocr Pract. 2011 Nov;17(Suppl 6):1-25. Accessed 04 Feb 2013. PMID: 22193047
  6. De Villiers TJ, Gass MLS, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric. 2013 Apr;16(2):203-204. PMID: 23488524
  7. Nelson HD. Assessing benefits and harms of hormone replacement therapy: clinical applications. JAMA. 2002 Aug;288(7):882-884. PMID: 12186606
  8. Morelli V, Naquin C. Alternative therapies for traditional disease states: menopause. Am Fam Physician. 2002 Jul;66(1):129-134. PMID: 12126027
  9. North American Menopause Society (NAMS). Amended report from the NAMS Advisory Panel on postmenopausal hormone therapy. Menopause. 2003 Jan;10(1):006-12. PMID: 12544671
  10. Nelson HD, Humphrey LL, Teutsch SM, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002 Aug;288(7):872-881. PMID: 12186605
  11. Pines A, Strurdee DW, Birkhäuser MH, et al. HRT in the early menopause: scientific evidence and common perceptions. Climacteric. 2008 Aug;11(4):267-272. PMID: 18645691
  12. North American Menopause Society (NAMS). Estrogen and progesterone use in postmenopausal women: Jul 2008 position statement of the North American Menopause Society. Menopause. 2008;15(4):584-603. PMID: 18580541
  13. Pradhan AD, Manson JE, Rossouw JE, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. JAMA. 2002 Aug;288(8):980-987. PMID: 12190368
  14. Practice Committee of the American Society of Reproductive Medicine. Estrogen and progesterone therapy in postmenopausal women. Fertil Steril. 2008 Nov;90(Suppl 3):S88-S102. PMID: 19007655
  15. Rymer J, Wilson R, Ballard K. Making decisions about hormone replacement therapy. BMJ. 2003 Feb;326(7384):322-326. PMID: 12574048
  16. Radtke JV, Terhost L, Cohen SM. The Menopause-Specific Quality of Life Questionnaire: psychometric evaluation among breast cancer survivors. Menopause. 2011 Mar;18(3):289-295. PMID: 20881889
  17. Roberts H. Managing the menopause. BMJ. 2007 Apr;334(7596):736-741. PMID: 17413174
  18. Schneider HP; Executive Committee of the IMS. The view of the International Menopause Society on the Women's Health Initiative. Climacteric. 2002 Sep;5(3):211-216. PMID: 12419078
  19. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003 May;289(20):2651-2662. PMID: 12771112
  20. Society of Obstetricians and Gynaecologists of Canada. Society of Obstetricians and Gynaecologists of Canada clinical practice guidelines: menopause and osteoporosis update 2009. J Obstet Gynaecol Can. 2009 Jan;31(1):S1-S48.
  21. Writing Group on behalf of Workshop Consensus Group. Aging, menopause, cardiovascular disease and HRT. International Menopause Society Consensus Statement. Climacteric. 2009 Oct;12(5):368-377. PMID: 19811229
  22. MedWorm
  23. MedWorm
  24. Kanis JA. FRAX WHO fracture risk assessment tool. Accessed 30 Apr 2013.
  25. Ministry of Health, Singapore Chapter of Obstetricians and Gynecologists, Academy of Medicine, Singapore. Clinical practice guidelines: hormone replacement therapy. MOH (Singapore). Apr 2004.
  26. Greene JG. Greene climacteric scale. Accessed 29 Apr 2013.
  27. Institute for Clinical Systems Improvement (ICSI). Health care guideline. Menopause and hormone therapy (HT): collaborative decision-making and management. 9th ed. ICSI. Oct 2008. Accessed 21 Jun 2010.
  28. Haines CJ, Fan S, Tang GWK, et al. HKCOG guidelines. Guidelines for the administration of hormone replacement therapy. HKCOG. Nov 2006. Accessed 21 Jun 2010.
  29. Berlin Center for Epidemiology and Health Research. Menopause rating scale. ZEG Berlin. Accessed 29 Apr 2013.
  30. Hilditch JR, Lewis JE. The Menopause-Specific Quality of Life Questionnaire. Jul 2012. Accessed 30 Apr 2013.
  31. American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 141: management of menopausal symptoms. Jan 2014. National Guideline Clearinghouse. 07 Feb 2014.
  32. Kaunitz AM. New guidance from ACOG for treatment of women with menopausal symptoms. NEJM Journal Watch. 13 Jan 2014.
  33. Tan D, Darmasetiawan S, Haines CJ, et al; Expert Panel on Menopause in Asian Women. Guidelines for hormone replacement therapy of Asian women during the menopausal transition and thereafter. Climacteric. 2006 Apr;9(2):146-151. doi: 10.1080/13697130600655852. PMID: 16698661
  34. Reid R, Abramson BL, Blake J, et al; Menopause and Osteoporosis Working Group; Society of Obstetricians and Gynaecologists of Canada. Managing menopause. J Obstet Gynaecol Can. 2014 Sep;36(9):830-838. PMID: 25222364
  35. National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation. 2014.
  36. National Institute for Health and Care Excellence (NICE). Menopause: diagnosis and management. NICE. 12 Nov 2015. Accessed 27 Apr 2016.
  37. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016 Apr;19(2):109-150. doi: 10.3109/13697137.2015.1129166. Accessed 03 May 2017. PMID: 26872610
  38. National Institute for Health and Care Excellence (NICE). Menopause. NICE. 09 Feb 2017. Accessed 03 May 2017.
  39. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause - 2017 update. Endocr Pract. 2017 Jul;23(7):869-880. doi: 10.4158/EP171828.PS. PMID: 28703650
  40. Garcia JT, Gonzaga F, Tan D, et al. Use of a multibotanical (Nutrafem) for the relief of menopausal vasomotor symptoms: a double-blind, placebo-controlled study. Menopause. 2010 Mar;17(2):303-308. doi: 10.1097/gme.0b013e3181bf8e92. PMID: 19934777
  41. Fait T. Menopause hormone therapy: latest developments and clinical practice. Drugs in Context. 2019;8:212551. doi: 10.7573/dic.212551. PMID: 30636965
  42. Martin KA, Barbieri RL. Treatment of menopausal symptoms with hormone therapy. UpToDate. 13 Apr 2019.
  43. Kagan R, Kellogg-Spadt S, Parish SJ. Practical treatment considerations in the management of genitourinary syndrome of menopause. Drugs Aging. 2019 Oct;36(10):897-908. doi: 10.1007/s40266-019-00700-w. PMID: 31452067
  44. Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020 Jan 30;382(5):446-455. doi: 10.1056/NEJMcp1714787. PMID: 31995690
  45. Academic Committee of the Korean Society of Menopause, Lee SR, Cho MK, Cho YJ, et al. The 2020 menopausal hormone therapy guidelines. J Menopausal Med. 2020 Aug;26(2):69-98. doi: 10.6118/jmm.20000. Accessed 32893509. PMID: 32893509
  46. Palacios S, Stevenson JC, Schaudig K, et al. Hormone therapy for first-line management of menopausal symptoms: practical recommendations. Womens Health (Lond). 2019;15:1-8. doi: 10.1177/1745506519864009. Accessed 17 May 2021. PMID: 31378196
  47. Obstetrical and Gynaecological Society of Malaysia (OGSM), Persatuan Menopos Malaysia, College of Obstetricians & Gynaecologists Malaysia. Clinical practice guidelines. Management of menopause in Malaysia. OGSM. 2022. Accessed 22 Jul 2022.
  48. Hamoda H, Panay N, Arya R, et al. The British Menopause Society & Women's Health Concern 2016 recommendations on hormone replacement therapy in menopausal women. Post Reproductive Health. 2016;22(4):165-183. doi: 10.1177/2053369116680501.
  49. Rowe IJ, Baber RJ. The effects of phytoestrogens on postmenopausal health. Climacteric. 2021 Feb;24(1):57-63. doi: 10.1080/13697137.2020.1863356. Accessed 14 Apr 2023. PMID: 33395316
  50. The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-794. doi: 10.1097/GME.0000000000002028. Accessed 04 Apr 2023. PMID: 35797481
Editor's Recommendations
Special Reports
Related Disease News